Improvement in health status with once-daily indacaterol/glycopyrronium 110/50 μg in COPD patients: real-world evidence from an observational study in Ireland
| Autor: | Karen McGrath, Seán Lacey, Shane Sullivan, Kevin Kelly, Brian O’Doherty, Jane Dorman, Simon Schmid, David Molony, Sarah Whelan |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Copd patients Health Status Muscarinic Antagonists 030204 cardiovascular system & hematology Quinolones Real world evidence Severity of Illness Index 03 medical and health sciences Pulmonary Disease Chronic Obstructive 0302 clinical medicine Internal medicine Surveys and Questionnaires medicine Humans In patient 030212 general & internal medicine Prospective Studies Adverse effect Adrenergic beta-2 Receptor Agonists Aged Aged 80 and over COPD business.industry General Medicine Middle Aged medicine.disease Glycopyrrolate Bronchodilator Agents Drug Combinations Treatment Outcome Indans Indacaterol Observational study Female Once daily business Ireland medicine.drug |
| Zdroj: | Irish journal of medical science. 188(4) |
| ISSN: | 1863-4362 |
| Popis: | Indacaterol/glycopyrronium (IND/GLY) 110/50 μg is a once-daily (o.d.) fixed-dose combination of long-acting β2-agonist/long-acting muscarinic antagonist approved in over 90 countries, including Ireland, for the management of COPD. The present study was conducted to evaluate health status of COPD patients, initiated on IND/GLY 110/50 μg o.d., using the Clinical COPD Questionnaire (CCQ) tool in a real-world primary care setting in Ireland. This was a real-world, prospective, open-label study. COPD patients aged > 40 years and with a smoking history of > 10 pack-years were included and switched to once-daily IND/GLY 110/50 μg. Enrolment of patients into the study occurred only after the decision had been made by the physician to prescribe IND/GLY 110/50 μg. Data were collected at baseline and Week 26. Health status was assessed using the validated CCQ. A total of 200 patients were included in study. The mean CCQ total score decreased from 2.36 at baseline to 1.44 at Week 26 (Δ, 0.92; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink